[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 905
76. Moodley M, Moodley K: Trends of histopathology of cervical cancer among women in Durban, South Africa. Eur J Gynaecol Oncol; 2009;30(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends of histopathology of cervical cancer among women in Durban, South Africa.
  • INTRODUCTION: Cervical squamous cell carcinoma has traditionally been the commonest histological type of cervical cancer.
  • Adenocarcinoma has recently been reported to occur with increasing frequency.
  • METHODS: This retrospective study was conducted on 2,930 patients with cervical cancer over an eight-year period (1995-2002) recruited from the combined Gynaecology Oncology Clinic at King Edward VIII Hospital (KEH), Pathology Laboratories at KEH, and from the private sector.
  • RESULTS: In the public sector squamous cell carcinoma was found to be the commonest type of cervical cancer irrespective of ethnicity and age.
  • In the private sector, a slightly higher proportion (38.8%) of women had adenocarcinoma, however since the total number of patients were small (85) there was no statistically significant increase in adenocarcinoma relative to squamous cell carcinoma.
  • There was no correlation between the documented risk factors i.e., smoking, contraception and human papillomavirus and histological type of cervical cancer.
  • Similarly, there was no statistically significant relationship between ethnicity, differentiation, type of cervical cancer and age of the patient in both sectors.
  • CONCLUSION: This study has not revealed an increasing incidence in cervical adenocarcinoma in the public setting.
  • However, in the private sector, a significant proportion of black women (38.8%) had adenocarcinoma.
  • All Asian women had adenocarcinoma while 25% of the white women had adenocarcinoma.
  • [MeSH-major] Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Child, Preschool. Female. Humans. Middle Aged. South Africa / epidemiology. Young Adult


77. Kim HG, Song H, Yoon DH, Song BW, Park SM, Sung GH, Cho JY, Park HI, Choi S, Song WO, Hwang KC, Kim TW: Cordyceps pruinosa extracts induce apoptosis of HeLa cells by a caspase dependent pathway. J Ethnopharmacol; 2010 Mar 24;128(2):342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE STUDY: Cordyceps is a parasitic fungus and has long been used as a traditional Chinese medicine to treat illnesses, promote longevity, increase athletic power, and relieve exhaustion and cancer.
  • In this study, we reveal the mechanisms underlying apoptosis induced by Cordyceps pruinosa butanol fraction (CPBF) in the human cervical adenocarcinoma cell line, HeLa.
  • CONCLUSIONS: These results indicate that apoptotic effects of CPBF on HeLa cells are mediated by mitochondria-dependent death-signaling pathway independent of reactive oxygen species, suggesting that CPBF might be effective as an anti-proliferative agent for cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138133.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytochrome c Group; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / bcl-2-Associated X Protein; 116110-46-4 / cytochrome c''; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


78. Sonoda K, Miyamoto S, Nakashima M, Wake N: The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci; 2008;13:1106-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RCAS1 is a receptor-binding cancer antigen which is expressed on human uterine cervical adenocarcinoma cell line (SiSo).
  • Finding a correlation between the expression of this gene and the overall survival of patients with 14 different types of cancer points to the clinical significance of this gene.
  • Moreover, the expression RCAS1 correlates with other clinicopathological parameters including the histological type of cancer, its differentiation, tumor size, clinical stage, the depth of invasion, lymphovascular space involvement, lymph node metastasis, and positive peritoneal cytological results.
  • The concentration of RCAS1 in serum or pleural effusions has been found to be significantly higher in patients with several different types of cancer as compared to normal controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981616.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human; 0 / Tn antigen
  • [Number-of-references] 78
  •  go-up   go-down


79. Tawfik El-Mansi M, Williams AR: Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer; 2006 May-Jun;16(3):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system.
  • We used a large series of cervical adenocarcinomas to investigate TMA technology in assessment of immunohistochemical staining.
  • A TMA was constructed using 273 archival paraffin blocks from 139 patients with 119 invasive and 20 adenocarcinoma in situ and 16 normal controls.
  • Our results suggest that TMAs can be successfully used for immunohistochemical studies of cervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Microarray Analysis / methods. Tissue Array Analysis / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Female. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Models, Biological. Molecular Diagnostic Techniques. Neoplasm Invasiveness / diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803510.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


80. Hurrell DP, Jamison J, Dobbs SP, McCluggage WG: Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy. Int J Gynecol Pathol; 2009 May;28(3):296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy.
  • We report a case in which a vaginal adenocarcinoma was discovered in a 67-year-old woman 16 years after hysterectomy for cervical adenocarcinoma in situ.
  • Both the vaginal and cervical lesions exhibited morphologic and immunohistochemical (CDX2-positive) features of intestinal differentiation.
  • Linear array human papillomavirus genotyping demonstrated the vaginal adenocarcinoma to contain human papillomavirus 45.
  • We believe the vaginal adenocarcinoma to be related to the cervical adenocarcinoma in situ and to represent recurrence of this.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / pathology


81. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer; 2010 Jun 8;102(12):1692-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.
  • BACKGROUND: To determine the prognostic factors and treatment outcomes of patients with early-stage adenocarcinoma (AdCa) of uterine cervix who underwent radical hysterectomy (RH).
  • METHODS: Patients with early-stage squamous cell carcinoma (SCCa) of the uterine cervix who underwent RH were compared with patients with AdCa by multivariate analysis.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery


82. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2008 Jul;110(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity.
  • Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen.
  • CONCLUSION: Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dexamethasone / therapeutic use. Disease Progression. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Pemetrexed. Treatment Outcome


8
Advertisement
4. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis


85. Zafrakas M, Papanikolaou AN, Venizelos ID, Kellartzis D, Agorastos T, Bontis JN: A rare case of renal cell carcinoma metastasizing to the uterine cervix. Eur J Gynaecol Oncol; 2009;30(2):239-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of renal cell carcinoma metastasizing to the uterine cervix.
  • Metastatic tumors to the uterine cervix originating from malignancies in other organs are very rare.
  • A case of a 45-year-old white woman presenting with vaginal bleeding, due to renal cell carcinoma metastasizing to the cervix, is reported.
  • The patient had been treated four years and five months earlier due to two primary malignancies: colon adenocarcinoma and renal cell carcinoma.
  • The possibility of metastasis from another primary should be considered in the differential diagnosis of tumors of the uterine cervix in order to plan optimal management.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Uterine Cervical Neoplasms / secondary


86. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol; 2007 May;31(5):664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
  • Endocervical-type mucinous adenocarcinoma (ECA) of the uterine cervix is defined as a tumor composed of cells resembling those of the endocervical glands, but recent studies have demonstrated that a minority of ECAs displays a gastric immunophenotype.
  • Fifty-three cases of mucinous adenocarcinoma of the uterine cervix (37 FIGO stage IB, 4 stage IIA, and 12 stage IIB) were reviewed and reevaluated using a newly established morphologic criteria for distinguishing gastric type adenocarcinoma, which was defined as a tumor showing clear and/or pale eosinophilic and voluminous cytoplasm, with distinct cell borders.
  • Following the current World Health Organization scheme (2003), 47 tumors (89%) were classified as ECA, 1 (2%) as intestinal type, 1 (2%) as mixed endocervical and intestinal type, and 4 (8%) as minimal deviation adenocarcinoma.
  • Twelve of 47 (26%) ECAs and all 4 minimal deviation adenocarcinomas, reclassified as gastric type using the novel criteria, were frequently positive for HIK1083 with a rate of 75% (12/16), whereas only 11% (4/37) of nongastric tumors were positive.
  • Patients with gastric-type adenocarcinomas had a significantly decreased 5-year disease-specific survival rate (30 vs. 77%; P<0.0001), and the gastric type morphology was related to a significant risk for disease recurrence compared with the nongastric type (P=0.001; HR, 4.5; 95% confidence interval, 1.42-14.2).
  • Mucinous adenocarcinoma of the uterine cervix with gastric immunophenotype can be a distinct morphologic variant showing an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460448.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Gastric Mucins
  •  go-up   go-down


87. Duska LR: Can we improve the detection of glandular cervical lesions: the role and limitations of the Pap smear diagnosis atypical glandular cells (AGC). Gynecol Oncol; 2009 Sep;114(3):381-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can we improve the detection of glandular cervical lesions: the role and limitations of the Pap smear diagnosis atypical glandular cells (AGC).
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / standards
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / pathology. Female. Humans


88. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


89. Belval CC, Barranger E, Dubernard G, Touboul E, Houry S, Daraï E: Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma. Gynecol Oncol; 2006 Sep;102(3):580-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma.
  • BACKGROUND: The risk of wound metastasis after laparoscopic management of early-stage cervical cancer is well known, but there are few data on peritoneal carcinomatosis of cervical adenocarcinoma.
  • CASE: We report the first case of peritoneal carcinomatosis occurring in a woman with FIGO stage Ib1 cervical adenocarcinoma who underwent laparoscopic type III radical hysterectomy and bilateral pelvic lymphadenectomy (sentinel node procedure) followed by vaginal brachytherapy.
  • CONCLUSION: Laparoscopy for cervical adenocarcinoma may carry a risk of peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy. Peritoneal Neoplasms / secondary. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624387.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • We concluded that abdominal radical trachelectomy may be a surgical option for early stage cervical cancer treatment in young women who wish to preserve fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Electrosurgery. Female. Fertility. Humans. Intraoperative Complications. Postoperative Complications. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


91. McCluggage WG, Harley I, Houghton JP, Geyer FC, MacKay A, Reis-Filho JS: Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome. J Clin Pathol; 2010 Oct;63(10):935-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome.
  • An unusual cervical adenocarcinoma is reported in a 50-year-old woman with a history of Peutz Jeghers syndrome.
  • The carcinoma contained two morphologically distinct and spatially separate components, one comprising typical well differentiated adenoma malignum and the other a moderately differentiated neoplasm, in keeping with gastric type adenocarcinoma.
  • It is believed that the component of gastric type adenocarcinoma arose through a process of dedifferentiation within adenoma malignum and we provide circumstantial molecular evidence in support of the interpretation that both components may be clonally related in that they displayed an extra copy of chromosome 7.
  • This raises the possibility of a relationship between these two uncommon types of cervical adenocarcinoma, both of which are thought to exhibit gastric differentiation.
  • [MeSH-major] Adenocarcinoma / pathology. Mixed Tumor, Malignant / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology


92. Pruski D, Kedzia W, Przybylski M, Józefiak A, Purol M, Spaczyński M: [Assessment of optoelectronic method and molecular test usefulness for cervical intraepithelial neoplasia and cervical cancer detection]. Ginekol Pol; 2010 Jun;81(6):426-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of optoelectronic method and molecular test usefulness for cervical intraepithelial neoplasia and cervical cancer detection].
  • INTRODUCTION: Biophysics and molecular biology are disciplines dynamically entering the area of cervical cancer prevention.
  • The combined test, comprising optoelectronic and molecular diagnostics, may play a significant role in the decrease of cervical cancer incidence and mortality.
  • OBJECTIVE: Assessment of the combined test usefulness--optoelectronic method and HPV test for the presence of oncogenic HPV types, in the detection of cervical intraepithelial neoplasia and cervical cancer.
  • MATERIAL AND METHOD: From August 2006 to October 2008 the study included 250 patients from the Laboratory of Pathophysiology of Uterine Cervix in Gynecology and Obstetrics Clinical Hospital of Karol Marcinkowski University of Medical Sciences.
  • RESULTS: Sensitivity of the combined test for low-grade intraepithelial changes in the area of squamous epithelium (CIN 1) was 81%, while for high-grade changes (CIN 2, CIN 3) and carcinoma planoepitheliale together with adenocarcinoma was 100%.
  • CONCLUSIONS: Optoelectronic and molecular diagnostics methods are useful in detecting neoplastic cervical changes.
  • Both methods may become a key diagnostic tool of basic and advanced level of cervical screening.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Cervix Uteri / pathology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Vaginal Smears / instrumentation. Vaginal Smears / methods
  • [MeSH-minor] Colposcopy. Female. Humans. Optics and Photonics. Poland. Precancerous Conditions / diagnosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


93. Barreth D, Schepansky A, Capstick V, Johnson G, Steed H, Faught W: Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. J Obstet Gynaecol Can; 2006 Dec;28(12):1095-1098
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study was to determine the risk of a clinically significant lesion associated with the diagnosis of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H) on cervical cytology (Pap smear).
  • A computerized database containing cytologic and histologic information for the health region was used to identify women with a diagnosis of ASC-H on a Pap smear performed between January 1 and December 31, 2002.
  • Patients were excluded if they had a diagnosis of cervical cancer, adenocarcinoma in situ (AIS), or high-grade squamous intraepithelial lesion (HSIL) prior to the index Pap smear.
  • Ninety-one patients had a previous diagnosis of cervical cancer, AIS, or HSIL and were excluded from analysis, and 12 patients on review did not have ASC-H.
  • In this group, the rates of histologically proven cervical lesions were 2.9% (15/517) for cervical cancer, 1.7% (9/517) for AIS, and 65.6% (339/517) for HSIL.
  • CONCLUSION: The diagnosis of ASC-H on Pap smear is associated with an appreciable risk of clinically significant disease.
  • Patients with an ASC-H Pap smear result should undergo timely colposcopic and histologic assessment to rule out HSIL, AIS, and cervical cancer.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Neoplasms, Squamous Cell / diagnosis. Precancerous Conditions / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Colposcopy. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Risk Factors. Vaginal Smears


94. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy


95. Pettersson BF, Andersson S, Hellman K, Hellström AC: Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer; 2010 May 15;116(10):2343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience.
  • BACKGROUND: This study is a representation of 90 years of experience with carcinoma of the uterine cervix in pregnancy.
  • The objective was to retrospectively study changes in the distribution of cervical carcinoma (CC) by age, disease stage, histopathology, survival, and the development of second primary cancers.
  • At the time of diagnosis, stage I CC was observed in 75.6% of patients during 1960 to 2004 compared with 24.8% of patients during 1914 to 1943.
  • [MeSH-major] Pregnancy Complications, Neoplastic / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Age Factors. Female. Humans. Incidence. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Squamous Cell / epidemiology. Neoplasms, Squamous Cell / mortality. Neoplasms, Squamous Cell / pathology. Pregnancy. Survivors


96. Poujade O, Morice P, Rouzier R, Madelenat P, Lecuru F, Muray JM, Mathevet P, Alran S, Salmon RJ, Reyal F: Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int J Gynecol Cancer; 2010 Jul;20(5):815-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study.
  • INTRODUCTION: Exclusive chemoradiotherapy (including brachytherapy) is the current standard of care for locoregionally advanced cervical cancer.
  • The aim of the present study was to evaluate the responsiveness and to identify factors predicting the response to concomitant chemoradiotherapy before surgery in cervical adenocarcinoma.
  • A total of 54 women with cervical adenocarcinoma stage IB2 to IIIB who had undergone concurrent chemoradiation therapy followed by surgical treatment were included.
  • RESULTS: The median (SD) age at diagnosis was 44.2 (12.4) years (range, 19.3-77 years).
  • CONCLUSIONS: Identification of predictive markers associated with incomplete response to neoadjuvant chemoradiotherapy in cervical adenocarcinoma may prove clinically useful and implement an individualized treatment plan.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Gynecologic Surgical Procedures. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606528.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


97. Kamaté B, Traoré CB, Diallo D, Sacko R, Toure M, Keita B, Teguete B, Traore Y, Diarra MH, Ouattara AT, Traoré AC, Mariko H, Dembele Y, Togola B, Tall K, Sanogo A, Diané M, Kaloga I, Traoré M, Dolo AI, Bayo S: [Extension of cervix cancer screening by visual methods to the community health centres in the district of Bamako]. Mali Med; 2008;23(4):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extension of cervix cancer screening by visual methods to the community health centres in the district of Bamako].
  • [Transliterated title] Extension du depistage du cancer du col uterin par inspection visuelle aux centres de sante communautaires du district de Bamako.
  • Cervix cancer remains a public health problem in developing countries.
  • These results are an assessment for multicentric study based on visual inspection of the cervix after application of acetiq acid (VIA) and lugol's iodine (VILI).
  • At all 177 biopsies were done, and histological diagnosis were: 67 dysplasias, 3 early invasive carcinomas, 69 invasive carcinomas and 38 inflammatory metaplasic lesions or nonconclusives aspects.
  • This study showed that screening of cervical cancer by visual inspection is workable at CSCOM level.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Community Health Centers / organization & administration. Mass Screening / organization & administration. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Acetic Acid. Adult. Biopsy. Coloring Agents. Female. Health Services Accessibility. Hospitals, University / organization & administration. Hospitals, University / statistics & numerical data. Humans. Iodides. Mali / epidemiology. Metaplasia. Middle Aged. Physical Examination. Prospective Studies. Staining and Labeling. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Dysplasia / epidemiology. Uterine Cervicitis / diagnosis. Uterine Cervicitis / epidemiology


98. Arellano-Llamas A, Garcia FJ, Perez D, Cantu D, Espinosa M, De la Garza JG, Maldonado V, Melendez-Zajgla J: High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer; 2006;6:256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Smac/DIABLO expression is associated with early local recurrence of cervical cancer.
  • BACKGROUND: In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo in a subset of cervical cancer patients.
  • We have now expanded this study and analyzed Smac/DIABLO expression in the primary lesions in 109 cervical cancer patients.
  • Seventy-eight samples corresponded to epidermoid cervical cancer and 31 to cervical adenocarcinoma.
  • RESULTS: Smac/DIABLO was expressed in more adenocarcinoma samples than squamous tumours (71% vs 50%; p = 0.037).
  • CONCLUSION: Smac/DIABLO expression is a potential marker for local recurrence in cervical squamous cell carcinoma patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / chemistry. Intracellular Signaling Peptides and Proteins / analysis. Mitochondrial Proteins / analysis. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry. Uterine Cervical Neoplasms / chemistry


99. Jiang L, Malpica A, Deavers MT, Guo M, Villa LL, Nuovo G, Merino MJ, Silva EG: Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries. Int J Gynecol Pathol; 2010 Mar;29(2):146-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.
  • The majority of endometrial endometrioid adenocarcinomas involving the cervix have tumor morphology that is similar in the endometrium and the endocervix.
  • We selected 14 cases of endometrial endometrioid adenocarcinomas involving the cervix with complete pathology material available from the years between 1968 and 2004.
  • Histologic features varied between the tumors in the endometrium and the endocervix in 8 cases, and 5 of these cases had uniform, dilated glands having a microcystic appearance in the cervix.
  • The immunohistochemical studies showed some differences between the endometrial and endocervical adenocarcinomas in 8 of the 12 cases, independent of differing or similar histologic features.
  • Clonality studies showed differences between the adenocarcinoma in the endometrium and the endocervix in 7 cases, including 5 cases with different histologic appearances; 2 cases had similar loss of heterozygosity patterns.
  • However, endometrial tumors involving the cervix and endocervical tumors unrelated to HPV are both negative for high-risk HPV.
  • [MeSH-major] Carcinoma, Endometrioid / virology. Endometrial Neoplasms / virology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173500.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


100. Lee HB, Lee YS, Lee KH, Kim CJ, Park JS: A case of advanced gynecologic pelvic tumors showing the diagnostic utility of HPV analysis. J Gynecol Oncol; 2009 Dec;20(4):251-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This may lead to difficulties in determining the origin of the cancer and to distinguish a synchronous neoplasm from a metastatic cancer in advanced cases.
  • Recently, we treated a 59-year-old patient with adenocarcinoma of the uterine cervix, endometrium, fallopian tubes, and ovaries.
  • It was difficult to determine whether the cancer was a single origin metastatic cancer or a synchronous neoplasm.
  • The patient was finally diagnosed with metastatic cancer that originated from the uterine cervix by human papillomavirus (HPV) test.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):281-94 [15725796.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):337-41 [10053104.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):829-36 [15010819.001]
  • [Cites] Tumour Biol. 2003 Nov-Dec;24(6):310-6 [15004491.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):672-5 [12915876.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):104-11 [12468350.001]
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1129-33 [12423833.001]
  • [Cites] Cancer Causes Control. 2001 May;12(4):335-41 [11456229.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):7-12 [14668543.001]
  • (PMID = 20041104.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2799026
  • [Keywords] NOTNLM ; Cervical adenocarcinoma / Human papillomavirus / Metastatic cancer / Synchronous neoplasm
  •  go-up   go-down






Advertisement